课题基金 / 基金详情

(131) IODINE-B1 RADIOIMMUNOTHERAPY OF ADVANCED NONHODGKIN'S LYMPHOMA

(131) IODINE-B1 RADIOIMMUNOTHERAPY OF ADVANCED NONHODGKIN'S LYMPHOMA
(131) 晚期非霍奇金淋巴瘤的碘 B1 放射免疫治疗
批准号：
6113398
负责人：
MARK S. KAMINSKI
金额：
$0.02万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6113398
关键词：
B cell lymphoma CD antigens clinical research combination cancer therapy dosage drug adverse effect drug screening /evaluation human subject human therapy evaluation iodine monoclonal antibody neoplasm /cancer immunotherapy neoplasm /cancer radiation therapy nonHodgkin's lymphoma radiotracer

项目摘要

项目成果

MARK S. KAMINSKI的其他基金

相似基金

相关文献

中文摘要
翻译
本研究的主要目的是确定在常规剂量化疗后复发或化疗无效的b细胞淋巴瘤患者中，131-I标记的单克隆抗cd20抗体的最大耐受放射免疫治疗剂量的肿瘤反应率。其他目的是评估这种放射性标记的抗b细胞抗体的肿瘤靶向潜力和毒性。
英文摘要
The main purpose of this study is to determine the tumor response rate of a maximally tolerated radioimmunotherapeutic dose of a monoclonal anti-CD20 antibody labeled with 131-I in patients with B-cell lymphoma who have relapsed after or have failed to respond to conventional-dose chemotherapy. Other goals are to assess the tumor targeting potential and the toxicity of this radiolabeled anti-B-cell antibody.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RETREATMENT OF NON HODGKINS LYMPHOMA W/ IODINE 131 ANTI B1 ANTIBODY
I 131 ANTI B1 ANTIBODY IN NON HODGKINS LYMPHOMA VS UNLABELED ANTI B1
(131) IODINE-B1 RADIOIMMUNOTHERAPY OF ADVANCED NONHODGKIN'S LYMPHOMA
RETREATMENT OF NON HODGKINS LYMPHOMA W/ IODINE 131 ANTI B1 ANTIBODY
海外基金